Increased in Vitro cytotoxicity of TNF-α analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan

Annals of the New York Academy of Sciences

Volumn 973, Issue , 2002, Pages 194-206

  Menart, Viktor ^a,b   Fonda, Irena ^b   Kenig, Maja ^a   Porekar, Vladka Gaberc ^b  

^a Lek dd   (Slovenia)

^b NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

Cancer therapy; Cell line L 929; Cytotoxicity; Heparan sulfate; Heparin sepharose; Proteoglycans; TNF analog; Tumor necrosis factor alpha

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARAN SULFATE; HEPARIN LYASE; LK 805; PROTEOGLYCAN; SEPHAROSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BINDING KINETICS; CELL SURFACE; CHEMICAL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; EXPERIMENTAL MODEL; FIBROBLAST CULTURE; MEMBRANE BINDING; MOUSE; MUTATION; NONHUMAN; TUMOR MODEL;

ANIMALIA;

EID: 0036963489     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04632.x     Document Type: Conference Paper

References (28)

1. EGGERMONT, A.M. 1998. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res. 18: 3899-3905.
2. LEJEUNE, F.J., C. RUEGG & D. LIENARD. 1998. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 10: 573-580.
3. NOVAKOVIC, S., V. MENART, V. GABERC-POREKAR, et al. 1997. New TNF-alpha analogues: a powerful but less toxic biological tool against tumours. Cytokine 9: 597-604.
4. CAREY, D.J. 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327: 1-16.
5. TUMOVA, S., A. WOODS& J.R. COUCHMAN. 2000. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int. J. Biochem. Cell Biol. 32: 269-288.
6. LINDAHL, U. 2000. 'Heparin' - from anticoagulant drug into the new biology. Glycoconjugate J. 17: 597-605.
7. IOZZO, R.V. & J.D. SANANTONIO. 2001. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108: 349-355.
8. SANDERSON, R.D. 2001. Heparan sulfate proteoglycans in invasion and metastasis. Semin. Cell Dev. Biol. 12: 89-98.
9. AKULA, S.M., N.P. PRAMOD, F.Z. WANG & B. CHANDRAN. 2001. Human herpesvirus 8 envelope-associated glycoprotein B interacts with heparan sulfate-like moieties. Virology 284: 235-249.
10. SAPHIRE, A.C.S., M.D. BOBARDT, Z. ZHANG, et al. 2001. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J. Virol. 75: 9187-9200.
11. MIKAMI, S., K. OHASHI, Y. USUI, et al. 2001. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn. J. Cancer Res. 92: 1062-1073.
12. FUJIYA, M., J. WATARI, T. ASHIDA, et al. 2001. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn. J. Cancer Res. 92: 1074-1081.
13. PARK, P.W., O. REIZES & M. BERNFIELD. 2000. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J. Biol. Chem. 275: 29923-29926.
14. FIORE, M.M. 2001. Cellular specificity for the activation of fibroblast growth factor-2 by heparan sulfate proteoglycan. Biochem. Biophys. Res. Commun. 284: 384-388.
15. MONGIAT, M., J. OTTO, R. OLDERSHAW, et al. 2001. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J. Biol. Chem. 276: 10263-10271.
16. BELEV, T.N., M. SINGH & J.E. MCCARTHY. 1991. A fully modular vector system for the optimization of gene expression in Escherichia coli. Plasmid 26: 147-150.
17. KUNKEL, T.A., J.D. ROBERTS & R.A. ZAKOUR. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. In Methods in Enzymology, Recombinant DNA, Part E. R. Wu & L. Grossman, Eds.:367-382. Academic Press, Inc. San Diego.
18. FLICK, D.A. & G.E. GIFFORD. 1984. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods 68: 167-175.
19. YAYON, A., M. KLAGSBRUN, J.D. ESKO, et al. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848.
20. FAIRBROTHER, W.J., M.A. CHAMPE, H.W. CHRISTINGER, et al. 1998. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6: 637-648.
21. ZHAO, M., T. ABDEL-RAZEK, M.F. SUN & D. GAILANI. 1998. Characterization of a heparin binding site on the heavy chain of factor XI. J. Biol. Chem. 273: 31153-31159.
22. SONCIN, F., D.J. STRYDOM & R. SHAPIRO. 1997. Interaction of heparin with human angiogenin. J. Biol. Chem. 272: 9818-9824.
23. NAKAMURA, S., T. MASEGI, M. FUKUOKA, et al. 1991. Interactions between novel tumor-necrosis-factor-alpha mutants and receptors on tumor and normal-cells. Agric. Biol. Chem. 55: 53-57.
24. CREASEY, A.A., L.V. DOYLE, M.T. REYNOLDS, et al. 1987. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res. 47: 145-149.
25. SIDHU, R.S. & A.P. BOLLON. 1989. Tumor necrosis factor analogs: identification of functional domains. Anticancer Res. 9: 1569-1576.
26. LANTZ, M., H. THYSELL, E. NILSSON & I. OLSSON. 1991. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J. Clin. Invest. 88: 2026-2031.
27. ILAG, L.L., A.S. NILSSON & C.F. IBANEZ. 2000. Engineering of the Heparin-Binding Domain of Neurotrophin-6 onto Nerve Growth Factor, http//cajal.mbb.ki.se/mnbneuro/hepNGF%20(HTML) 1-5.
28. MULLOY, B. & R.J. LINHARDT. 2001. Order out of complexity - protein structures that interact with heparin. Curr. Opin. Struct. Biol. 11: 623-628.